Literature DB >> 24758595

Medication-assisted therapies--tackling the opioid-overdose epidemic.

Nora D Volkow1, Thomas R Frieden, Pamela S Hyde, Stephen S Cha.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24758595     DOI： 10.1056/NEJMp1402780

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  350 in total

1.  Reasons for Benzodiazepine Use Among Persons Seeking Opioid Detoxification.

Authors:  Michael D Stein; Mitika Kanabar; Bradley J Anderson; Anna Lembke; Genie L Bailey
Journal:  J Subst Abuse Treat       Date:  2016-06-16

2.  Buprenorphine Use and Spending for Opioid Use Disorder Treatment: Trends From 2003 to 2015.

Authors:  Andrew W Roberts; Brendan Saloner; Stacie B Dusetzina
Journal:  Psychiatr Serv       Date:  2018-05-08       Impact factor: 3.084

3.  Mortality among heroin users and users of other internationally regulated drugs: A 27-year follow-up of users in the Epidemiologic Catchment Area Program household samples.

Authors:  Catalina Lopez-Quintero; Kimberly B Roth; William W Eaton; Li-Tzy Wu; Linda B Cottler; Martha Bruce; James C Anthony
Journal:  Drug Alcohol Depend       Date:  2015-09-03       Impact factor: 4.492

4.  The impact of addiction medications on treatment outcomes for persons with co-occurring PTSD and opioid use disorders.

Authors:  Elizabeth C Saunders; Mark P McGovern; Chantal Lambert-Harris; Andrea Meier; Bethany McLeman; Haiyi Xie
Journal:  Am J Addict       Date:  2015-09-21

5.  Resistance exercise decreases heroin self-administration and alters gene expression in the nucleus accumbens of heroin-exposed rats.

Authors:  Mark A Smith; Gaylen E Fronk; Jean M Abel; Ryan T Lacy; Sarah E Bills; Wendy J Lynch
Journal:  Psychopharmacology (Berl)       Date:  2018-02-02       Impact factor: 4.530

6.  Associations between neighborhood-level factors and opioid-related mortality: A multi-level analysis using death certificate data.

Authors:  Michael William Flores; Benjamin Lê Cook; Brian Mullin; Gabriel Halperin-Goldstein; Aparna Nathan; Kertu Tenso; Zev Schuman-Olivier
Journal:  Addiction       Date:  2020-06-03       Impact factor: 6.526

7.  Letting the sun shine on patient voices: Perspectives about medications for opioid use disorder in Florida.

Authors:  Amanda Sharp; Melissa Carlson; Veronica Howell; Kathleen Moore; Zev Schuman-Olivier
Journal:  J Subst Abuse Treat       Date:  2020-12-11

8.  A comparison of buprenorphine and psychosocial treatment outcomes in psychosocial and medical settings.

Authors:  Ned J Presnall; D A Patterson Silver Wolf; Derek S Brown; Sara Beeler-Stinn; Richard A Grucza
Journal:  J Subst Abuse Treat       Date:  2019-06-15

9.  NIDA Clinical Trials Network CTN-0051, Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT): Study design and rationale.

Authors:  Joshua D Lee; Edward V Nunes; Patricia Novo Mpa; Genie L Bailey; Gregory S Brigham; Allan J Cohen; Marc Fishman; Walter Ling; Robert Lindblad; Dikla Shmueli-Blumberg; Don Stablein; Jeanine May; Dagmar Salazar; David Liu; John Rotrosen
Journal:  Contemp Clin Trials       Date:  2016-08-10       Impact factor: 2.226

10.  Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees.

Authors:  Hillary Samples; Arthur Robin Williams; Mark Olfson; Stephen Crystal
Journal:  J Subst Abuse Treat       Date:  2018-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.